ATAI Life Sciences is a German biotech startup that creates, invests in, and acquires businesses developing psychedelic therapies with a focus on mental health. The company was founded in 2018 by Christian Angermayer, who serves as the company's chairman; Lars Wilde; Florian Brand, who serves as CEO; and Dr. Srinivas Rao, who serves as Chief Scientific Officer.
ATAI currently finances several companies conducting research on a wide range of mental health fields:
- Treatment Resistant Depression
- Cognitive Impairment associated with Schizophrenia
- Opioid Use Disorder
- Generalized Anxiety Disorder
- Mild Traumatic Brain Injury
- Post Traumatic Stress Disorder